FLX Bio scores $60 mln Series C

South San Francisco-based FLX Bio Inc, a biopharmaceutical company focused on activating the immune system against cancer, has secured $60 million in Series C financing. The investors included GV, The Column Group, Kleiner Perkins, Topspin Partners and Celgene Corporation.

ManagersNorth AmericaUSHealthcareBriefs